Context Therapeutics Inc (CNTX) Stock Price, Quote & News

Company Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 201...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 225 7416

Website: www.contexttherapeutics.com

Address:

2001 Market Street, Suite 3915 Unit #15, Philadelphia, United States

DARKP00L Dec. 10 at 5:27 PM

$CNTX this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

SpencerF Dec. 9 at 8:00 PM

$CNTX haha false hope. Back to 0.00 we go. Bye money

0 · Reply

VA_24 Dec. 9 at 3:37 PM

$CNTX Still diluting Up 2 million shares from my last post

0 · Reply

SpencerF Dec. 8 at 6:15 PM

$CNTX still mandatory to do a 50 cent double bottom?

0 · Reply

albertoguerrero10 Dec. 5 at 12:59 AM

$CNTX

0 · Reply

SpencerF Dec. 4 at 5:47 PM

$CNTX woohoo off to pennyland we go. Can’t wait for $0.00 hehe

0 · Reply

VA_24 Dec. 2 at 4:13 PM

$CNTX 👀

0 · Reply

Jl37 Nov. 28 at 3:06 PM

$CNTX this is the only thing not moving big time today for me! Come on man!

0 · Reply

VA_24 Nov. 24 at 7:38 PM

$CNTX Last few days volume had been great Hopefully something is brewing Last week there was a 300K buy Now 200

0 · Reply

Okaldirimj Nov. 19 at 3:48 AM

$CNTX Are we going below 1?

1 · Reply

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Nov 5, 2025, 4:15 PM EST - 5 weeks ago

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Oct 28, 2025, 8:00 AM EDT - 6 weeks ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

SKYE

Oct 28, 2025, 7:30 AM EDT - 6 weeks ago

Context Therapeutics to Participate in Upcoming Investor Conferences

Oct 6, 2025, 7:30 AM EDT - 2 months ago

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Oct 3, 2025, 4:15 PM EDT - 2 months ago

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 6, 2025, 4:11 PM EDT - 4 months ago

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

Jun 10, 2025, 7:10 AM EDT - 6 months ago

Context Therapeutics: Undervalued Cancer Fighter

Jun 2, 2025, 7:30 AM EDT - 6 months ago

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

May 29, 2025, 7:30 AM EDT - 7 months ago

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

May 12, 2025, 4:38 PM EDT - 7 months ago

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2025, 4:09 PM EDT - 7 months ago

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

May 5, 2025, 4:05 PM EDT - 7 months ago

Context Therapeutics Announces Chief Medical Officer Transition

Apr 30, 2025, 7:30 AM EDT - 8 months ago

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Apr 9, 2025, 7:30 AM EDT - 8 months ago

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Mar 26, 2025, 4:02 PM EDT - 9 months ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 20, 2025, 4:22 PM EDT - 9 months ago

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Jan 14, 2025, 4:58 PM EST - 11 months ago

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Jan 13, 2025, 7:30 AM EST - 11 months ago

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Nov 6, 2024, 4:06 PM EST - 1 year ago

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Aug 7, 2024, 4:17 PM EDT - 1 year ago

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Jul 10, 2024, 2:06 PM EDT - 1 year ago

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

May 8, 2024, 4:06 PM EDT - 1 year ago

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 2, 2024, 7:31 AM EDT - 1 year ago

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Apr 1, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Mar 21, 2024, 7:43 AM EDT - 1 year ago

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Nov 9, 2023, 4:15 PM EST - 2 years ago

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 1, 2023, 7:30 AM EDT - 2 years ago

Context Therapeutics to Participate in Two August 2023 Investor Conferences

May 10, 2023, 4:39 PM EDT - 2 years ago

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

Apr 18, 2023, 10:15 AM EDT - 2 years ago

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Apr 3, 2023, 7:30 AM EDT - 2 years ago

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Mar 22, 2023, 5:08 PM EDT - 2 years ago

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Mar 15, 2023, 7:30 AM EDT - 2 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Feb 6, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Jan 31, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

Jan 9, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Jan 4, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Dec 8, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Nov 29, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Nov 21, 2022, 9:11 AM EST - 3 years ago

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Nov 9, 2022, 4:14 PM EST - 3 years ago

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in the ThinkEquity Conference

Sep 27, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

DARKP00L Dec. 10 at 5:27 PM

$CNTX this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

SpencerF Dec. 9 at 8:00 PM

$CNTX haha false hope. Back to 0.00 we go. Bye money

0 · Reply

VA_24 Dec. 9 at 3:37 PM

$CNTX Still diluting Up 2 million shares from my last post

0 · Reply

SpencerF Dec. 8 at 6:15 PM

$CNTX still mandatory to do a 50 cent double bottom?

0 · Reply

albertoguerrero10 Dec. 5 at 12:59 AM

$CNTX

0 · Reply

SpencerF Dec. 4 at 5:47 PM

$CNTX woohoo off to pennyland we go. Can’t wait for $0.00 hehe

0 · Reply

VA_24 Dec. 2 at 4:13 PM

$CNTX 👀

0 · Reply

Jl37 Nov. 28 at 3:06 PM

$CNTX this is the only thing not moving big time today for me! Come on man!

0 · Reply

VA_24 Nov. 24 at 7:38 PM

$CNTX Last few days volume had been great Hopefully something is brewing Last week there was a 300K buy Now 200

0 · Reply

Okaldirimj Nov. 19 at 3:48 AM

$CNTX Are we going below 1?

1 · Reply

Jl37 Nov. 19 at 3:00 AM

$CNTX geez

0 · Reply

Jl37 Nov. 12 at 2:58 PM

$CNTX I’m ok with the low volume with nobody selling!

0 · Reply

Jl37 Nov. 10 at 2:58 PM

$CNTX

0 · Reply

dudereally Nov. 9 at 4:22 PM

$BCAB $CNTX I don’t see anything about BCAB It appears to all just be drugs that they’re working on.

3 · Reply

BiotechValues Nov. 9 at 12:11 AM

$BCAB $CNTX PR yesterday about BCAB's program. Can access the poster on their site: https://ir.contexttherapeutics.com/news-releases/news-release-details/context-therapeutics-highlights-ct-95-and-ct-202-programs-2025

0 · Reply

LabPsycho Nov. 8 at 3:17 PM

$CNTX @BiotechValues Thanks for your post - I was wondering how that partnership was going. Do you know status of BCAB delisting / extension notices if any?

1 · Reply

BiotechValues Nov. 6 at 2:03 PM

$BCAB triggered a $2M milestone in October from $CNTX partnership. Anything helps as we await the ph3 deal due by end of year. From $CNTX 10q below. On track to initiate ph1 study of $BCAB's Nectin-4 program in q2 2026.

1 · Reply

JarvisFlow Nov. 6 at 1:22 PM

D. Boral Capital has updated their rating for Context Therapeutics ( $CNTX ) to Buy with a price target of 9.

0 · Reply

Jl37 Nov. 6 at 1:06 PM

$CNTX maybe good news with earnings…

0 · Reply

JarvisFlow Nov. 6 at 11:51 AM

HC Wainwright & Co. updates rating for Context Therapeutics ( $CNTX ) to Buy, target set at 4 → 5.

0 · Reply

d_risk Nov. 5 at 9:16 PM

$CNTX - Context Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors CNTX flags new risks of costly patent litigation, expanded U.S. tariff threats now targeting pharmaceuticals, and regulatory uncertainty from possible FDA budget cuts, HHS leadership changes, and a new government efficiency commission. #Pharmaceuticals #U.S.Tariffs #FDABudgetCuts #RegulatoryUncertainty #PatentLitigation 🟢 Added 🟠 Removed https://d-risk.ai/CNTX/10-Q/2025-11-05

0 · Reply

Jl37 Nov. 4 at 2:54 PM

$CNTX losing my as now.

1 · Reply

Market Cap	95.55M
Revenue (ttm)	0.00
Net Income (ttm)	-26.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	546,600
Avg Vol	463,230
Day's Range	N/A - N/A
Shares Out	91.88M
Stochastic %K	34%
Beta	1.94
Analysts	Strong Sell
Price Target	$5.33